TY - JOUR
T1 - TCPA v3.0
T2 - An integrative platform to explore the pan-cancer analysis of functional proteomic data
AU - Chen, Mei Ju May
AU - Li, Jun
AU - Wang, Yumeng
AU - Akbani, Rehan
AU - Lu, Yiling
AU - Mills, Gordon B.
AU - Liang, Han
N1 - Funding Information:
* This study was supported by the National Institutes of Health (CA098258, CA217842, and CA210950 to G.B.M.; CA175486 to H.L.; CA209851 to H.L. and G.B.M.; and CCSG grant CA016672), the Lorraine Dell Program in Bioinformatics for Personalization of Cancer Medicine, and the Adelson Medical Research Foundation (to G.B.M.). G.B.M. has sponsored research support from AstraZeneca, Critical Outcomes Technology, Karus, Illumina, Immunomet, Nanostring, Tarveda, and Immunomet and is on the Scientific Advisory Board for AstraZeneca, Critical Outcomes Technology, ImmunoMet, Ionis, Nuevolution, Symphogen, and Tarveda. H.L. is a shareholder and scientific advisor of Precision Scientific Ltd., (Beijing, China) and Eagle Nebula Inc. ‖ To whom correspondence should be addressed: The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77030, Tel: 713-745-9815; Fax: 713-563-4242; E-mail: hliang1@ mdanderson.org. ** The authors contributed equally to this work.
Publisher Copyright:
© 2019 Chen et al.
PY - 2019
Y1 - 2019
N2 - Reverse-phase protein arrays represent a powerful functional proteomics approach to characterizing cell signaling pathways and understanding their effects on cancer development. Using this platform, we have characterized ∼8,000 patient samples of 32 cancer types through The Cancer Genome Atlas and built a widely used, open-access bioinformatic resource, The Cancer Proteome Atlas (TCPA). To maximize the utility of TCPA, we have developed a new module called "TCGA Pan-Cancer Analysis," which provides comprehensive protein-centric analyses that integrate protein expression data and other TCGA data across cancer types. We further demonstrate the value of this module by examining the correlations of RPPA proteins with significantly mutated genes, assessing the predictive power of somatic copy-number alterations, DNA methylation, and mRNA on protein expression, inferring the regulatory effects of miRNAs on protein expression, constructing a co-expression network of proteins and pathways, and identifying clinically relevant protein markers. This upgraded TCPA (v3.0) will provide the cancer research community with a more powerful tool for studying functional proteomics and making translational impacts.
AB - Reverse-phase protein arrays represent a powerful functional proteomics approach to characterizing cell signaling pathways and understanding their effects on cancer development. Using this platform, we have characterized ∼8,000 patient samples of 32 cancer types through The Cancer Genome Atlas and built a widely used, open-access bioinformatic resource, The Cancer Proteome Atlas (TCPA). To maximize the utility of TCPA, we have developed a new module called "TCGA Pan-Cancer Analysis," which provides comprehensive protein-centric analyses that integrate protein expression data and other TCGA data across cancer types. We further demonstrate the value of this module by examining the correlations of RPPA proteins with significantly mutated genes, assessing the predictive power of somatic copy-number alterations, DNA methylation, and mRNA on protein expression, inferring the regulatory effects of miRNAs on protein expression, constructing a co-expression network of proteins and pathways, and identifying clinically relevant protein markers. This upgraded TCPA (v3.0) will provide the cancer research community with a more powerful tool for studying functional proteomics and making translational impacts.
UR - http://www.scopus.com/inward/record.url?scp=85071349984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071349984&partnerID=8YFLogxK
U2 - 10.1074/mcp.RA118.001260
DO - 10.1074/mcp.RA118.001260
M3 - Article
C2 - 31201206
AN - SCOPUS:85071349984
SN - 1535-9476
VL - 18
SP - S15-S25
JO - Molecular and Cellular Proteomics
JF - Molecular and Cellular Proteomics
IS - 8
ER -